Home › Compare › FEMFD vs ABBV
FEMFD yields 440.53% · ABBV yields 3.06%● Live data
📍 FEMFD pulled ahead of the other in Year 1
Combined, FEMFD + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FEMFD + ABBV for your $10,000?
FE Battery Metals Corp., a junior resource company, explores and develops mineral properties in Canada. It explores for silver, gold, cobalt, tungsten, zinc, lithium, and molybdenum deposits. The company has an option to acquire a 100% interest in the Red Lake Gold Property that comprises 94 mining cell claims covering an area of approximately 1,880 hectares located in Ontario, Canada. It also has 100% owned Kaslo Property that covers an area of 4,000 hectares located in British Columbia, Canada. In addition, the company has 100% interest in the Abitibi Lithium property comprising 241 mineral claims covering approximately 12,779 hectares; the Titan Gold Property consisting of 80 mining claims covering an area of approximately 4,402 hectares; the Augustus Lithium property comprising 21 mineral claims covering approximately 937 hectares; and the Canadian Lithium property consisting of 12 mineral claims covering area of approximately 671 hectares located in Quebec, Canada. Further, it has 100% interest in the McNeely Lithium Property consisting of 66 mining claims covering a total area of 2,276 hectares; the Falcon Lake property comprising 48 mineral claims covering approximately 987 hectares; and the Electron Lithium property consisting of 435 mineral claims covering approximately 20,357 hectares located in Quebec, Canada. FE Battery Metals Corp. was incorporated in 1966 and is headquartered in Vancouver, Canada.
Full FEMFD Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.